Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate-weekly incretin dosing for weight maintenance after weight loss
ACTRN12625000609459Phase 2Recruiting
- Sponsor
- Monash University
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of semaglutide and tirzepatide in obesity (2 arms), sponsored by Monash University. Primary endpoint: Weight maintenance at 24 weeks. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12625000609459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000609459.